Thrombolysis for pulmonary embolism: Past, present and future

Thrombosis and Haemostasis

Volumn 103, Issue 5, 2010, Pages 877-883

  Lankeit, Mareike ^a   Konstantinides, Stavros ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Plasminogen activators; Pulmonary embolism; Thrombolysis thrombolytic agents; Thrombosis; Venous thrombosis

Indexed keywords

FATTY ACID BINDING PROTEIN; FIBRINOLYTIC AGENT; HEPARIN; TROPONIN; ANTICOAGULANT AGENT;

ANGIOGRAPHY; ANTICOAGULATION; BLEEDING; BLOOD CLOT LYSIS; BLOOD PRESSURE; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; ECHOCARDIOGRAPHY; FIBRINOLYTIC THERAPY; HEART MUSCLE INJURY; HEART VENTRICLE FUNCTION; HEMODYNAMICS; HUMAN; LUNG EMBOLISM; PRIORITY JOURNAL; PROGNOSIS; REVIEW; HEMORRHAGE; HYPOTENSION; META ANALYSIS (TOPIC); MORTALITY; PATHOPHYSIOLOGY; PULMONARY EMBOLISM; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR;

ANTICOAGULANTS; HEMORRHAGE; HUMANS; HYPOTENSION; META-ANALYSIS AS TOPIC; PULMONARY EMBOLISM; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; THROMBOLYTIC THERAPY;

EID: 77952057702     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-01-0005     Document Type: Review

References (91)

1. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-593.
2. Anderson FA, Jr., Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case- fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151: 933-938.
3. White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107 (Suppl 1): I4-I8.
4. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353: 1386-1389. (Pubitemid 29192409)
5. Kasper W, Konstantinides S, Geibel A, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 1997; 30: 1165-1171.
6. British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. Lancet 1992; 340: 873-876.
7. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326: 1240-1245.
8. Aujesky D, Jimenez D, Mor MK, et al. Weekend versus weekday admission and mortality after acute pulmonary embolism. Circulation 2009; 119: 962-968.
9. Laporte S, Mismetti P, Decousus H, et al. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation 2008; 117: 1711-1716.
10. Office of the Surgeon General. Acting Surgeon General issues 'call to action to prevent deep vein thrombosis and pulmonary embolism'. September 2008. Accessed March 1, 2010 at: http://www.surgeongeneral.gov/news/pressreleases/ pr20080915.html.
11. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-764.
12. Cohen AT, Edmondson RA, Phillips MJ, et al. The changing pattern of venous thromboembolic disease. Haemostasis 1996; 26: 65-71. (Pubitemid 26139622)
13. Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ 1991; 302: 709-711.
14. Kasper W, Konstantinides S, Geibel A, et al. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 1997; 77: 346-349. (Pubitemid 27208175)
15. Konstantinides S. Pulmonary embolism: impact of right ventricular dysfunction. Curr Opin Cardiol 2005; 20: 496-501. (Pubitemid 41565332)
16. Miller RL, Das S, Anandarangam T, et al. Association between right ventricular function and perfusion abnormalities in hemodynamically stable patients with acute pulmonary embolism. Chest 1998; 113: 665-670. (Pubitemid 28130939)
17. McIntyre KM, Sasahara AA. Determinants of right ventricular function and hemodynamics after pulmonary embolism. Chest 1974; 65: 534-543.
18. McIntyre KM, Sasahara AA. The hemodynamic response to pulmonary embolism in patients without prior cardiopulmonary disease. Am J Cardiol 1971; 28: 288-294.
19. Greyson C, Xu Y, Cohen J, et al. Right ventricular dysfunction persists following brief right ventricular pressure overload. Cardiovasc Res 1997; 34: 281-288. (Pubitemid 27241572)
20. Schmitto JD, Doerge H, Post H, et al. Progressive right ventricular failure is not explained by myocardial ischemia in a pig model of right ventricular pressure overload. Eur J Cardiothorac Surg 2009; 35: 229-234.
21. Chung T, Connor D, Joseph J, et al. Platelet activation in acute pulmonary embolism. J Thromb Haemost 2007; 5: 918-924. (Pubitemid 46691719)
22. Smulders YM. Pathophysiology and treatment of haemodynamic instability in acute pulmonary embolism: the pivotal role of pulmonary vasoconstriction. Cardiovasc Res 2000; 48: 23-33.
23. Konstantinides S. Clinical practice. Acute pulmonary embolism. N Engl J Med 2008; 359: 2804-2813.
24. Torbicki A, Perrier A, Konstantinides SV, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29: 2276-2315.
25. Kucher N, Rossi E, De Rosa M, et al. Massive pulmonary embolism. Circulation 2006; 113: 577-582.
26. Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995; 108: 978-981.
27. Grifoni S, Olivotto I, Cecchini P, et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation 2000; 101: 2817-2822. (Pubitemid 30396012)
28. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 454S-545S. (Pubitemid 351892971)
29. Miller GA, Sutton GC, Kerr IH, et al. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. Br Heart J 1971; 33: 616.
30. The urokinase pulmonary embolism trial. A national cooperative study. Circulation 1973; 47 (2 Suppl): II1-108.
31. Tibbutt DA, Davies JA, Anderson JA, et al. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonay embolism. Br Med J 1974; 1: 343-347.
32. Ly B, Arnesen H, Eie H, et al. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand 1978; 203: 465-470. (Pubitemid 8358211)
33. Marini C, Di Ricco G, Rossi G, et al. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial. Respiration 1988; 54: 162-173.
34. Levine M, Hirsh J, Weitz J, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990; 98: 1473-1479.
35. Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators. Chest 1990; 97: 528-533.
36. Dalla-Volta S, Palla A, Santolicandro A, et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol 1992; 20: 520-526.
37. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993; 341: 507-511.
38. Meneveau N, Seronde MF, Blonde MC, et al. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest 2006; 129: 1043-1050.
39. Daniels LB, Parker JA, Patel SR, et al. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol 1997; 80: 184-188. (Pubitemid 27329218)
40. Dalen JE, Banas JS, Jr., Brooks HL, et al. Resolution rate of acute pulmonary embolism in man. N Engl J Med 1969; 280: 1194-1199.
41. Konstantinides S, Tiede N, Geibel A, et al. Comparison of alteplase versus heparin for resolution of major pulmonary embolism. Am J Cardiol 1998; 82: 966-970. (Pubitemid 28480783)
42. Konstantinides S, Geibel A, Heusel G, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347: 1143-1150.
43. Kanter DS, Mikkola KM, Patel SR, et al. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest 1997; 111: 1241-1245.
44. Sors H, Pacouret G, Azarian R, et al. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. Chest 1994; 106: 712-717.
45. Goldhaber SZ, Kessler CM, Heit JA, et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol 1992; 20: 24-30.
46. Meyer G, Sors H, Charbonnier B, et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism [see comments]. J Am Coll Cardiol 1992; 19: 239-245.
47. Goldhaber SZ, Kessler CM, Heit J, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988; 2: 293-298.
48. Verstraete M, Miller GA, Bounameaux H, et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988; 77: 353-360. (Pubitemid 18060044)
49. Urokinase-streptokinase embolism trial. Phase 2 results. A cooperative study. J Am Med Assoc 1974; 229: 1606-1613.
50. Konstantinides S, Marder VJ. Thrombolysis in venous thromboembolism. In: Hemostasis and Thrombosis. Lippincott Williams and Wilkins 2006: 1317-1329.
51. Stein PD, Hull RD, Raskob G. Risks for major bleeding from thrombolytic therapy in patients with acute pulmonary embolism. Consideration of noninvasive management [see comments]. Ann Intern Med 1994; 121: 313-317.
52. Hamel E, Pacouret G, Vincentelli D, et al. Thrombolysis or heparin therapy in massive pulmonary embolism with right ventricular dilation: results from a 128-patient monocenter registry. Chest 2001; 120: 120-125. (Pubitemid 32744867)
53. Meyer G, Gisselbrecht M, Diehl JL, et al. Incidence and predictors of major hemorrhagic complications from thrombolytic therapy in patients with massive pulmonary embolism. Am J Med 1998; 105: 472-477. (Pubitemid 29013331)
54. Meneveau N, Schiele F, Metz D, et al. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up. J Am Coll Cardiol 1998; 31: 1057-1063. (Pubitemid 28212506)
55. Meneveau N, Schiele F, Vuillemenot A, et al. Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction. Eur Heart J 1997; 18: 1141-1148.
56. Goldhaber SZ, Agnelli G, Levine MN. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group. Chest 1994; 106: 718-724.
57. Tebbe U, Graf A, Kamke W, et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J 1999; 138: 39-44. (Pubitemid 29331118)
58. Tebbe U, Bramlage P, Graf A, et al. Desmoteplase in acute massive pulmonary thromboembolism. Thromb Haemost 2009; 101: 557-562.
59. Becattini C, Agnelli G, Salvi A, et al. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res 2010; 125: e82-86.
60. Wan S, Quinlan DJ, Agnelli G, et al. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 2004; 110: 744-749.
61. Eid-Lidt G, Gaspar J, Sandoval J, et al. Combined clot fragmentation and aspiration in patients with acute pulmonary embolism. Chest 2008; 134: 54-60.
62. Kucher N, Goldhaber SZ. Mechanical catheter intervention in massive pulmonary embolism: proof of concept. Chest 2008; 134: 2-4.
63. Rose PS, Punjabi NM, Pearse DB. Treatment of right heart thromboemboli. Chest 2002; 121: 806-814.
64. Chartier L, Bera J, Delomez M, et al. Free-floating thrombi in the right heart: diagnosis, management, and prognostic indexes in 38 consecutive patients. Circulation 1999; 99: 2779-2783.
65. Kucher N, Goldhaber SZ. Management of massive pulmonary embolism. Circulation 2005; 112: e28-e32.
66. Ribeiro A, Lindmarker P, Juhlin-Dannfelt A, et al. Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J 1997; 134: 479-487.
67. Kucher N, Rossi E, De Rosa M, et al. Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher. Arch Intern Med 2005; 165: 1777-1781.
68. ten Wolde M, Sohne M, Quak E, et al. Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism. Arch Intern Med 2004; 164: 1685-1689.
69. Sanchez O, Trinquart L, Colombet I, et al. Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. Eur Heart J 2008; 29: 1569-1577. (Pubitemid 351881988)
70. Binder L, Pieske B, Olschewski M, et al. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation 2005; 112: 1573-1579. (Pubitemid 41324518)
71. Sanchez O, Trinquart L, Caille V, et al. Prognostic Factors for Pulmonary Embolism: The PREP Study, A Prospective Multicenter Cohort Study. Am J Respir Crit Care Med 2010; 181: 168-173.
72. Schoepf UJ, Kucher N, Kipfmueller F, et al. Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation 2004; 110: 3276-3280. (Pubitemid 39525077)
73. Kucher N, Printzen G, Doernhoefer T, et al. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 2003; 107: 1576-1578. (Pubitemid 36397323)
74. Kucher N, Printzen G, Goldhaber SZ. Prognostic Role of Brain Natriuretic Peptide in Acute Pulmonary Embolism. Circulation 2003; 107: 2545.
75. Pruszczyk P, Kostrubiec M, Bochowicz A, et al. N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism. Eur Respir J 2003; 22: 649-653. (Pubitemid 37258545)
76. ten Wolde M, Tulevski II, Mulder JW, et al. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation 2003; 107: 2082-2084.
77. Kucher N, Goldhaber SZ. Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation 2003; 108: 2191-2194. (Pubitemid 37363033)
78. Giannitsis E, Katus HA. Risk stratification in pulmonary embolism based on biomarkers and echocardiography. Circulation 2005; 112: 1520-1521.
79. Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med 2008; 178: 425-430.
80. Korff S, Katus HA, Giannitsis E. Differential diagnosis of elevated troponins. Heart 2006; 92: 987-993.
81. Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation 2007; 116: 427-433. (Pubitemid 47196548)
82. Jimenez D, Uresandi F, Otero R, et al. Troponin-based risk stratification of patients with acute nonmassive pulmonary embolism: systematic review and metaanalysis. Chest 2009; 136: 974-982.
83. Lankeit M, Konstantinides S. Tenecteplase can be given to patients with intermediate-risk pulmonary embolism - But should it? Thromb Res 2009; Epub ahead of press.
84. Storch J, Thumser AE. The fatty acid transport function of fatty acid-binding proteins. Biochim Biophys Acta 2000; 1486: 28-44. (Pubitemid 30336790)
85. Alhadi HA, Fox KA. Do we need additional markers of myocyte necrosis: the potential value of heart fatty-acid-binding protein. QJM 2004; 97: 187-198.
86. Pelsers MM, Hermens WT, Glatz JF. Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta 2005; 352: 15-35. (Pubitemid 40093855)
87. Puls M, Dellas C, Lankeit M, et al. Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism. Eur Heart J 2007; 28: 224-229. (Pubitemid 46269875)
88. Kaczynska A, Pelsers MM, Bochowicz A, et al. Plasma heart-type fatty acid binding protein is superior to troponin and myoglobin for rapid risk stratification in acute pulmonary embolism. Clin Chim Acta 2006; 371: 117-123. (Pubitemid 44162903)
89. Dellas C, Puls M, Lankeit M, et al. Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism. J Am Coll Cardiol 2010; in press.
90. Lankeit M, Kempf T, Dellas C, et al. Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med 2008; 177: 1018-1025. (Pubitemid 351717597)
91. Lankeit M, Konstantinides S. Thrombolysis for hemodynamically stable patients with pulmonary embolism: still searching for the intermediate-risk group. Thromb Res 2009; 124: 647-648.